SSA
OBIO icon

Schonfeld Strategic Advisors’s Orchestra BioMed OBIO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.5K Buy
+10,953
New +$46.6K ﹤0.01% 1980
2022
Q3 		– Sell
-42,998
Closed -$428K – 3103
2022
Q2 		$428K Buy
+42,998
New +$427K ﹤0.01% 1449

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Schonfeld Strategic Advisors's OBIO Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Orchestra BioMed (OBIO) in Q1 2026: 10,953 shares worth $46.5K. The stake represents ﹤0.01% of the portfolio and ranks #1980 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in OBIO as recently as Q2 2022.

Schonfeld Strategic Advisors first reported a position in OBIO in Q2 2022 and has held it in 2 quarters since. The position peaked at $428K in Q2 2022. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Schonfeld Strategic Advisors held 10,953 shares of Orchestra BioMed worth $46.5K as of Q1 2026.
  • Orchestra BioMed was a new Schonfeld Strategic Advisors position in Q1 2026.
  • Orchestra BioMed made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1980 holding.
  • Schonfeld Strategic Advisors first reported a position in Orchestra BioMed in Q2 2022 and has held it in 2 quarters since.
  • Schonfeld Strategic Advisors's Orchestra BioMed position peaked at $428K in Q2 2022.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.